Merck Scraps Its COVID Vaccine; Says it’s More Effective to Get the Virus and Recover Naturally

Vaccine manufacturer Merck has abandoned development of two coronavirus vaccines, saying that, after extensive research, it found that the shots were less effective than contracting the virus and allowing the body to naturally produce antibodies. Merck is instead planning to produce oral antiviral drugs. It is hoped that the drugs will protect patients from the damage of an overactive immune response to the virus. Merck will receive around $356-million from taxpayers to fast-track these drugs.

[There is no hint in Merck’s announcement that adverse reactions – including permanent disability and death – in the first patients to receive the vaccine had anything to do with this sudden change in policy, and Merck goes out of its way to say that the vaccine was well tolerated during the trial, but there is good reason to be skeptical. In spite of every attempt by mainstream media to block stories of adverse reactions, many accounts were faithfully reported in the independent media and widely circulated. We have no doubt that, in time, many more of the suppressed cases eventually will be reported. If this happens, there could be tens of thousands of enraged husbands, wives, children and parents of loved ones lost to the vaccines – and the executives at Merck may wisely have decided to make a bold move to avoid being the targets of such anger. We shall see.] -GEG

Vaccine manufacturer Merck has abandoned development of two coronavirus vaccines, saying that after extensive research it was concluded that the shots offered less protection than just contracting the virus itself and developing antibodies.

The company announced that the shots V590 and V591 were ‘well tolerated’ by test patients, however they generated an ‘inferior’ immune system response in comparison with natural infection.

The company stated that instead it will focus on research into therapeutic drugs labeled as MK-7110 and MK-4482.

The drugs aim to protect patients from the damage of an overactive immune response to the virus.

“Interim results from a Phase 3 study showed a greater than 50 percent reduction in the risk of death or respiratory failure in patients hospitalized with moderate to severe COVID-19,” the company’s statement noted of the MK-7110 drug.

Merck is to receive around $356 million from the US government to fast-track production of the potential treatments under Operation Warp Speed.

Read full article here…